株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

臨床開発の新興市場:ブラジル、ロシア、インド、中国(BRIC)

Emerging Markets Clinical Development Series: Brazil, Russia, India and China (BRIC)

発行 Cutting Edge Information 商品コード 143474
出版日 ページ情報 英文 275 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
臨床開発の新興市場:ブラジル、ロシア、インド、中国(BRIC) Emerging Markets Clinical Development Series: Brazil, Russia, India and China (BRIC)
出版日: 2010年11月30日 ページ情報: 英文 275 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、ブラジル、ロシア、インド、中国のBRIC諸国における臨床開発市場について分析し、各国別の臨床開発戦略と動向、およびプロファイルをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

  • BRIC諸国のスコアリング
  • 調査方法
  • 参加企業
  • レポートレイアウト
  • プロファイルレイアウト
  • BRIC諸国における治験実施:成功のための提言

ブラジル

  • 臨床環境概要
  • 臨床開発戦略
  • 臨床開発プロファイル

ロシア

  • 臨床環境概要
  • 臨床開発戦略
  • ベストプラクティス
  • 臨床開発プロファイル

インド

  • 臨床環境概要
  • 臨床開発戦略
  • 臨床開発プロファイル

中国

  • 臨床環境概要
  • 臨床開発戦略
  • 臨床開発プロファイル
目次
Product Code: PH143

Abstract

The next frontier of global industry expansion makes its home in Brazil, Russia, India and China (BRIC). Imagine the impact of a patient pool that numbers 3 billion - an immediate cure for patient shortages (or recruitment challenges) that plague studies in North America and Western Europe, unparalleled access to untapped patient populations, and new opportunities to meet the growing medical needs of these countries. Despite vast promise as the next major growth opportunity for life sciences companies, the BRIC countries collectively represent a daunting challenge to new product development strategists and clinical operations teams. Any number of unknowns - unfamiliar regulatory guidelines, intellectual property concerns, time and distance barriers, and tolerance of dishonest business practices - can cause companies to hesitate to invest in these emerging markets or keep them out altogether. Confidently tap into the potential of the BRIC markets, fulfill protocol, and ultimately, realize significant cost and time savings. Expand your understanding of BRIC, individually and as a whole, using rankings data and best practices to map out a winning clinical strategy:

  • Eliminate confusion Weigh the advantages and drawbacks of different countries and examine rankings for 13 cllnical factors to enable strategic decision- making. Gain quick access to relevant demographics and economics information for a comprehensive analysis of the clinical environment.
  • Master trial management Learn from top executives' firsthand experiences - both successes and misfires. Recommendations show your team how to improve CRO selection, management and oversight, and more. Explore 23 in-depth profiles and find one that matches your company' s situation.
  • Clarify misperceptions Differences in cultural attitudes and behavior impact trial success. Knowledge and awareness go a long way in cultivating strong and beneficial relationships with local CROs.

Table of Contents

  • 13 Executive Summary
  • 15 Scoring BRIC
  • 33 Study Methodology
  • 34 Participating Companies
  • 35 Report Layout
  • 36 Profile Layout
  • 39 Running Trials in BRIC Countries: Key Recommendations for Success
  • 45 Brazil
  • 46 Clinical Environment Overview
  • 61 Clinical Development Strategy
  • 80 Clinical Development Profiles
  • 101 Russia
  • 103 Clinical Environment Overview
  • 116 Clinical Development Strategy
  • 132 Best Practices
  • 136 Clinical Development Profiles
  • 161 India
  • 162 Clinical Environment Overview
  • 175 Clinical Development Strategy
  • 196 Clinical Development Profiles
  • 225 China
  • 226 Clinical Environment Overview
  • 240 Clinical Development Strategy
  • 256 Clinical Development Profiles

CHARTS AND GRAPHICS

Executive Summary

  • 15 Figure E.1: BRIC Population Compared to US and 5 EU Countries Scoring BRIC
  • 16 Figure E.2: Number of Studies Registered by Region
  • 17 Figure E.3: Number of Studies Registered in BRIC Countries
  • 18 Figure E.4: Scoring BRIC: Patient Access
  • 18 Figure E.5: Scoring BRIC: Patient Retention
  • 20 Figure E.6: Scoring BRIC: Regulatory Environment
  • 21 Figure E.7: Scoring BRIC: Intellectual Property Laws/Practice
  • 22 Figure E.8: Scoring BRIC: Cultural Concerns
  • 23 Figure E.9: Scoring BRIC: Communication/Language
  • 25 Figure E.10: Scoring BRIC: Trial Technology Infrastructure
  • 25 Figure E.11: Scoring BRIC: Supply Chain Management
  • 27 Figure E.12: Scoring BRIC: Available Knowledge Base
  • 28 Figure E.13: Scoring BRIC: Data Standards
  • 29 Figure E.14: Scoring BRIC: Investigator Standards
  • 29 Figure E.15: Scoring BRIC: Site Management Standards
  • 31 Figure E.16: Average Percent of Budget Saved by Running a Site in BRIC Countries
  • 31 Figure E.17: Average Percentage of Time Saved by Running a Site in BRIC Countries
  • 32 Figure E.18: Scoring BRIC: Anticipated Cost

Brazil

  • 46 Table 1.1: Key Demographic Figures for Brazil, 2010

Clinical Environment Overview

  • 47 Figure 1.1: Change in Life Expectancy: Brazil (1960 - 2050)
  • 48 Table 1.2: Top 10 Causes of Death in Brazil, 2002
  • 49 Figure 1.2: Ethnicities in Brazil (2000 Census)
  • 52 Table 1.3: Key Economic Figures, 2009
  • 54 Table 1.4: Key Healthcare System Figures, 2005 - 2009
  • 55 Figure 1.3: Brazil' s Healthcare Spending as a Percent of GDP (2009)
  • 56 Figure 1.4: Health Spending by Sector (2005)
  • 58 Figure 1.5: Brazil' s Share of the Latin American Pharmaceutical Market (2009)
  • 61 Figure 1.6: Percentage of Budget Saved by Running a Trial in Brazil

Clinical Development Strategy

  • 62 Figure 1.7: Percentage of Time Saved by Running a Trial in Brazil
  • 64 Figure 1.8: Assigning Clinical Development Responsibilities for Brazil
  • 67 Figure 1.9: Importance of Factors that Impact Clinical Trial Environment for Companies Operating in Brazil
  • 68 Figure 1.10: Scoring Brazil: Clinical Environment Scores
  • 74 Figure 1.11: Importance of Factors that Impact Trial Operations for Companies Operating in Brazil
  • 74 Figure 1.12: Scoring Brazil: Trial Operations Scores
  • 76 Figure 1.13: Percentage of Total Trial Patients Enrolled in Brazil

Clinical Development Profiles

  • 80 Figure 1.14: Profile 1: Company Background
  • 81 Figure 1.15: Profile 1: Experience in BRIC
  • 82 Figure 1.16: Profile 1: Clinical Strategy in Brazil
  • 83 Figure 1.17: Profile 1: Scorecard for Brazil
  • 84 Figure 1.18: Profile 2: Company Background
  • 85 Figure 1.19: Profile 2: Experience in BRIC
  • 86 Figure 1.20: Profile 2: Clinical Strategy in Brazil
  • 87 Figure 1.21: Profile 2: Scorecard for Brazil
  • 88 Figure 1.22: Profile 3: Company Background
  • 89 Figure 1.23: Profile 3: Experience in BRIC
  • 90 Figure 1.24: Profile 3: Clinical Strategy in Brazil
  • 91 Figure 1.25: Profile 3: Scorecard for Brazil
  • 92 Figure 1.26: Profile 4: Company Background
  • 93 Figure 1.27: Profile 4: Experience in BRIC
  • 94 Figure 1.28: Profile 4: Clinical Strategy in Brazil
  • 95 Figure 1.29: Profile 4: Scorecard for Brazil
  • 96 Figure 1.30: Profile 5: Company Background
  • 97 Figure 1.31: Profile 5: Experience in BRIC
  • 98 Figure 1.32: Profile 5: Clinical Strategy in Brazil
  • 99 Figure 1.33: Profile 5: Scorecard for Brazil

Russia

Clinical Environment Overview

  • 103 Table 2.1: Key Demographic Figures for Russia (2010)
  • 104 Figure 2.1: Change in Life Expectancy: Russia (1960-2050)
  • 105 Table 2.2: Top 10 Causes of Death in Russia (2002)
  • 106 Figure 2.2: Ethnicities in Russia (2002 Census)
  • 109 Table 2.3: Key Economic Figures (2009)
  • 111 Table 2.4: Key Healthcare System Figures (2005 - 2009)
  • 112 Figure 2.3: Russia' s Healthcare Spending as a Percentage of GDP (2006)
  • 113 Figure 2.4: Russia' s Health Spending by Sector (2005)

Clinical Development Strategy

  • 117 Figure 2.5: Percent of Total Trial Patients Enrolled in Russia
  • 118 Figure 2.6: Percentage of Budget Saved by Running Trial in Russia
  • 119 Figure 2.7: Percentage of Time Saved by Running Trial in Russia
  • 121 Figure 2.8: Assigning Clinical Development Responsibilities for Russia
  • 123 Figure 2.9: Importance of Factors that Impact Clinical Trial Environment for Companies Operating in Russia
  • 124 Figure 2.10: Scoring Russia: Clinical Environment Scores
  • 128 Figure 2.11: Importance of Factors that Impact Trial Operations for Companies Operating in Russia
  • 129 Figure 2.12: Scoring Russia: Trial Operations Scores

Clinical Development Profiles

  • 136 Figure 2.13: Profile 6: Company Background
  • 137 Figure 2.14: Profile 6: Experience in BRIC
  • 138 Figure 2.15: Profile 6: Clinical Strategy in Russia
  • 139 Figure 2.16: Profile 6: Scorecard for Russia
  • 140 Figure 2.17: Profile 7: Company Background
  • 141 Figure 2.18: Profile 7: Experience in BRIC
  • 142 Figure 2.19: Profile 7: Clinical Strategy in Russia
  • 143 Figure 2.20: Profile 7: Scorecard for Russia
  • 144 Figure 2.21: Profile 8: Company Background
  • 145 Figure 2.22: Profile 8: Experience in BRIC
  • 146 Figure 2.23: Profile 8: Clinical Strategy in Russia
  • 147 Figure 2.24: Profile 8: Scorecard for Russia
  • 148 Figure 2.25: Profile 9: Company Background
  • 149 Figure 2.26: Profile 9: Experience in BRIC
  • 150 Figure 2.27: Profile 9: Clinical Strategy in Russia
  • 151 Figure 2.28: Profile 9: Scorecard for Russia
  • 152 Figure 2.29: Profile 10: Company Background
  • 153 Figure 2.30: Profile 10: Experience in BRIC
  • 154 Figure 2.31: Profile 10: Clinical Strategy in Russia
  • 155 Figure 2.32: Profile 10: Scorecard for Russia
  • 156 Figure 2.33: Profile 11: Company Background
  • 157 Figure 2.34: Profile 11: Experience in BRIC
  • 158 Figure 2.35: Profile 11: Clinical Strategy in Russia
  • 159 Figure 2.36: Profile 11: Scorecard for Russia

India

Clinical Environment Overview

  • 163 Table 3.1: Key Demographic Figures for India (2010)
  • 164 Figure 3.1: Change in Life Expectancy (1960-2050)
  • 165 Table 3.2: Top Ten Causes of Death in India (2002)
  • 167 Figure 3.2: Ethnicities in India (2000 Census)
  • 169 Table 3.3: Key Economic Figures (2009)
  • 170 Figure 3.3: India' s Healthcare Spending as a Percent of GDP (2006)
  • 171 Figure 3.4: Health Spending by Sector (2005)
  • 172 Table 3.4: Key Healthcare System Figures (2005 - 2009)

Clinical Development Strategy

  • 176 Figure 3.5: Assigning Clinical Development Responsibilities for India
  • 181 Figure 3.6: Importance of Factors that Impact Clinical Trial Environment for Companies Operating in India
  • 182 Figure 3.7: Scoring India: Clinical Environment Scores
  • 189 Figure 3.8: Importance of Factors that Impact Trial Operations for Companies Operating in India
  • 189 Figure 3.9: Scoring India: Trial Operations Scores
  • 191 Figure 3.10: Percent of Total Trial Patients Enrolled in India
  • 194 Figure 3.11: Percentage of Budget Saved by Running a Trial in India
  • 194 Figure 3.12: Percentage of Time Saved by Running a Trial in India

Clinical Development Profiles

  • 196 Figure 3.13: Profile 12: Company Background
  • 197 Figure 3.14: Profile 12: Experience in BRIC
  • 198 Figure 3.15: Profile 12: Clinical Strategy in India
  • 199 Figure 3.16: Profile 12: Scorecard for India
  • 200 Figure 3.17: Profile 13: Company Background
  • 201 Figure 3.18: Profile 13: Experience in BRIC
  • 202 Figure 3.19: Profile 13: Clinical Strategy in India
  • 203 Figure 3.20: Profile 13: Scorecard for India
  • 204 Figure 3.21: Profile 14: Company Background
  • 205 Figure 3.22: Profile 14: Experience in BRIC
  • 206 Figure 3.23: Profile 14: Clinical Strategy in India
  • 207 Figure 3.24: Profile 14: Scorecard for India
  • 208 Figure 3.25: Profile 15: Company Background
  • 209 Figure 3.26: Profile 15: Experience in BRIC
  • 210 Figure 3.27: Profile 15: Clinical Strategy in India
  • 211 Figure 3.28: Profile 15: Scorecard for India
  • 212 Figure 3.29: Profile 16: Company Background
  • 213 Figure 3.30: Profile 16: Experience in BRIC
  • 214 Figure 3.31: Profile 16: Clinical Strategy in India
  • 215 Figure 3.32: Profile 16: Scorecard for India
  • 216 Figure 3.33: Profile 17: Company Background
  • 217 Figure 3.34: Profile 17: Experience in BRIC
  • 218 Figure 3.35: Profile 17: Clinical Strategy in India
  • 219 Figure 3.36: Profile 17: Scorecard for India
  • 220 Figure 3.37: Profile 18: Company Background
  • 221 Figure 3.38: Profile 18: Experience in BRIC
  • 222 Figure 3.39: Profile 18: Clinical Strategy in India
  • 223 Figure 3.40: Profile 18: Scorecard for India

China

Clinical Environment Overview

  • 226 Table 4.1: Key Demographic Figures for China (2010)
  • 227 Figure 4.1: Change in Life Expectancy: China (1960 - 2050)
  • 228 Table 4.2: Top 10 Causes of Death in China (2002)
  • 229 Figure 4.2: Ethnicities in China (2000 Census)
  • 232 Table 4.3: China' s Key Economic Figures (2009)
  • 234 Table 4.4: China' s Key Healthcare System Figures, 2005-2009
  • 235 Figure 4.3: China Healthcare Spending as a Percentage of GDP (2009)
  • 236 Figure 4.4: China' s Health Spending by Sector (2005)

Clinical Development Strategy

  • 242 Figure 4.5: Percentage of Budget Saved by Running a Trial in China
  • 242 Figure 4.6: Percentage of Time Saved by Running a Trial in China
  • 243 Figure 4.7: Assigning Clinical Development Responsibilities for China
  • 245 Figure 4.8: Scoring China: Clinical Environment Scores
  • 246 Figure 4.9: Importance of Factors that Impact Clinical Trial Environment for Companies Operating in China
  • 251 Figure 4.10: Importance of Factors that Impact Trial Operations for Companies Operating in China
  • 252 Figure 4.11: Scoring China: Trial Operations Scores
  • 255 Figure 4.12: Percent of Total Trial Patients Enrolled in China

Clinical Development Profiles

  • 256 Figure 4.13: Profile 19: Company Background
  • 257 Figure 4.14: Profile 19: Experience in BRIC
  • 258 Figure 4.15: Profile 19: Clinical Strategy in China
  • 259 Figure 4.16: Profile 19: Scorecard for China
  • 260 Figure 4.17: Profile 20: Company Background
  • 261 Figure 4.18: Profile 20: Experience in BRIC
  • 262 Figure 4.19: Profile 20: Clinical Strategy in China
  • 263 Figure 4.20: Profile 20: Scorecard for China
  • 264 Figure 4.21: Profile 21: Company Background
  • 265 Figure 4.22: Profile 21: Experience in BRIC
  • 266 Figure 4.23: Profile 21: Clinical Strategy in China
  • 267 Figure 4.24: Profile 21: Scorecard for China
  • 268 Figure 4.25: Profile 22: Company Background
  • 269 Figure 4.26: Profile 22: Experience in BRIC
  • 270 Figure 4.27: Profile 22: Clinical Strategy in China
  • 271 Figure 4.28: Profile 22: Scorecard for China
  • 272 Figure 4.29: Profile 23: Company Background
  • 273 Figure 4.30: Profile 23: Experience in BRIC
  • 274 Figure 4.31: Profile 23: Clinical Strategy in China
  • 275 Figure 4.32: Profile 23: Scorecard for China
Back to Top